Metroplex Clinical Research Center Posts Record Profits Since Re-purchase 

 DALLAS, TEXAS-Metroplex Clinical Research Center (MCRC), a multi-specialty clinical research site in Dallas, has enjoyed a 250 percent increase in business since site executives announced plans to reclaim its assets from Radiant Research in March 2007. Last year's re-purchase came eight years after Seattle-based Radiant Research assumed control of MCRC in a series of site acquisitions and mergers in 1999.   
   
  	"MCRC has spent 30 years building a reputation in Phase II-IV rheumatology studies and has expanded that expertise to Phase I studies since the buy-back," said Medical Director Stanley B. Cohen, M.D. 
   
  Located on the campus of UT Southwestern at St. Paul Medical Center in Dallas, MCRC is a mainstay in the medical community. An ongoing partnership with recruitment and retention provider D. Anderson Company has led to a series of study accomplishments. Since its inception, the site has successfully completed more than 770 Phase I-IV multi-specialty clinical studies, including more than 300 studies in rheumatic disease. The MCRC database contains the names of more than 3,000 healthy subjects and more than 19,500 individuals who have participated in clinical research studies or expressed an interest in participation.
   
  "Over the last year the physicians at MCRC have become more involved in Phase I research," explained Medical Director Roy Fleischmann, M.D. "This early phase research is critical for determining the absorption and metabolism of new therapies as well as establishing the potential future dose of the new therapies. Based on the data from these trials, doses are picked for the later stage studies which involve several hundreds of patients." 
   
  Headed by Drs. Fleischmann and Cohen, MCRC staff includes 10 board-certified doctors, two nurse practitioners, seven study coordinators, a regulatory specialist, a patient recruitment specialist, quality control personnel, a full-service X-ray department with bone density testing, a full-service laboratory, and an onsite infusion unit. The 16,000-square-foot MCRC complex includes overnight accommodations for up to four patients as well as recreational and lounge facilities. 
   
  Site executives say strategic alliances with key industry players have helped MCRC achieve measurable success. Diana Anderson, president and CEO of patient recruitment and retention provider D. Anderson Company, partnered with Drs. Cohen and Fleischmann to facilitate the re-purchase. With more than 18 years of experience spanning more than 30 countries, DAC is a leader in the global clinical trials industry.
   
  "We look forward to the future and new opportunities to grow our site, diversify our therapeutic specialties, and lay the groundwork to establish additional research facilities," said Chad Fragle, CEO of MCRC. 
   
  For more information about Metroplex Clinical Research Center, visit www.mcrcdallas.com 

News

Metroplex Clinical Research Center (MCRC), a multi-specialty clinical research site in Dallas, has enjoyed a 250 percent increase in business since site executives announced plans to reclaim its assets from Radiant Research in March 2007.